A Phase 3 interventional study of Aprepitant 125 mg and Aprepitant 80 mg in Chemotherapy Induced Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2018-09-25.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing aprepitant in Vomiting — 3 open to participants now, 3 under way, 1 of them phase 3. Aprepitant · Vomiting.
Among the 61 studies testing aprepitant in Vomiting, this one is the 10th largest by enrollment, is one of 8 that started in 2011, is one of 15 in phase 3, and was the 33rd registered.
794 studies on the registry are indexed under Vomiting; 99 are open to participants now.
Browse Vomiting studies →3 of the 61 studies testing aprepitant in Vomiting are open now, in 2 countries. Recruiting first, the newest first:
Sir Mortimer B. Davis - Jewish General Hospital · Sites in Canada
Ages 18+
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–75
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.
This study: 6 Months to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 307 is above the median of 103 across 674 interventional studies indexed under Vomiting.
Median enrollment 92 across the 61 interventional studies. Of the 45 that completed or were terminated, 25 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 61 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
29 studies in Vomiting by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 29 finished, 20 (69%) have results posted.
Among the 29 studies in Vomiting by Merck & Co., Inc, this one is the 13th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2011, is one of 10 in phase 3, and was the 22nd registered.
Merck & Co., Inc’s Vomiting studies by the year they started, since 2002.
1 of the studies testing aprepitant in Vomiting that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371728Sir Mortimer B. Davis - Jewish General HospitalEffect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 61 studies testing aprepitant in Vomiting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 29 in Vomiting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare the safety and efficacy of a three-day oral aprepitant regimen (aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the 120 hours following the initiation of chemotherapy in pediatric participants. Those who complete this first cycle of treatment and meet certain eligibility criteria will have the option of continuing for 5 additional cycles of open-label aprepitant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cycle 1:
randomization. A female who is of agrees to remain abstinent or use a barrier form of for at least 14 days prior to, throughout, and for at least one month following the last dose of study medication
Optional Cycles 2-6:
Exclusion Criteria:
Cycle 1:
Optional Cycles 2-6:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cycle 1: Participants 12 to 17 years of age, Day 1: aprepitant 125 mg capsule orally (PO) + ondansetron, Days 2 to 3: aprepitant 80 mg capsule PO. Participants 6 months to \<12 years of age, Day 1: aprepitant powder for suspension (PFS), 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: aprepitant PFS, 2.0 mg/kg (up to 80 mg). Optional Cycles 2-6: Open-label aprepitant administered in the same manner as in Cycle 1.
Drug: Aprepitant 125 mg · Drug: Aprepitant 80 mg · Drug: Aprepitant powder for suspension (PFS) · Drug: Ondansetron · Drug: Emetogenic chemotherapy
Cycle 1: Participants 12 to 17 years of age, Day 1: matching placebo for aprepitant 125 mg capsule oral (PO) + ondansetron Days 2 to 3: matching placebo for aprepitant 80 mg capsule PO. Participants 6 months to \<12 years of age, Day 1: matching placebo PFS: 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: matching placebo PFS: 2.0 mg/kg (up to 80 mg). Optional Cycles 2-6: Open-label aprepitant administered in the same manner as in Cycle 1.
Drug: Ondansetron · Drug: Placebo for Aprepitant 125 mg · Drug: Placebo for Aprepitant 80 mg · Drug: Placebo for Aprepitant PFS · Drug: Emetogenic chemotherapy
On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
Also known as: MK-0869, Emend®
On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
Also known as: MK-0869, Emend®
On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
Also known as: MK-0869, Emend®
Day 1: Administered according to product label for pediatric usage or local standard of care
Also known as: Zofran™
On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used."
Percentage of Participants With a Complete Response in the Delayed Phase of Cycle 1
Delayed Phase was defined as 25-120 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the delayed phase of Cycle 1.
Time frame: 25 to 120 hours after the start of chemotherapy
Percentage of Participants With a Complete Response in the Acute Phase of Cycle 1
Acute phase was defined as 0 to 24 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the acute phase of Cycle 1.
Time frame: 0 to 24 hours after initiation of chemotherapy
Percentage of Participants With a Complete Response in the Overall Phase of Cycle 1
Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the overall phase of Cycle 1.
Time frame: 0 to 120 hours after initiation of chemotherapy
Percentage of Participants With No Vomiting in the Overall Phase of Cycle 1
Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. No vomiting was defined as no emesis or retching or dry heaves in the overall phase of Cycle 1.
Time frame: 0 to 120 hours after initiation of chemotherapy
| Milestone | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Started | 155 | 152 |
| Received study treatment | 152 | 150 |
| Completed | 150 | 149 |
| Not completed | 5 | 3 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Milestone | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Started | 171 | 0 |
| Completed | 46 | 0 |
| Not completed | 125 | 0 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Completed chemotherapy regimen | 51 | 0 |
| Withdrew: Did not meet additional criteria | 25 | 0 |
| Withdrew: Did not respond to chemotherapy regimen | 4 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 19 | 0 |
| Withdrew: Protocol violation | 4 | 0 |
| Withdrew: Withdrawal by subject | 18 | 0 |
Delayed Phase was defined as 25-120 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the delayed phase of Cycle 1.
| Percentage of participants | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Percentage of Participants With a Complete Response in the Delayed Phase of Cycle 1 | 50.7 | 26.0 |
Acute phase was defined as 0 to 24 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the acute phase of Cycle 1.
| Percentage of participants | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Percentage of Participants With a Complete Response in the Acute Phase of Cycle 1 | 66.4 | 52.0 |
Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the overall phase of Cycle 1.
| Percentage of participants | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Percentage of Participants With a Complete Response in the Overall Phase of Cycle 1 | 40.1 | 20.0 |
Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. No vomiting was defined as no emesis or retching or dry heaves in the overall phase of Cycle 1.
| Percentage of participants | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Percentage of Participants With No Vomiting in the Overall Phase of Cycle 1 | 46.7 | 21.3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aprepitant Regimen Cycle 1 | — | 46/152 (30.3%) | 88/152 (57.9%) |
| Control Regimen Cycle 1 | — | 41/150 (27.3%) | 84/150 (56%) |
| Aprepitant Regimen Cycles 2-6 | — | 84/170 (49.4%) | 136/170 (80%) |
| Event | Aprepitant Regimen Cycle 1 | Control Regimen Cycle 1 | Aprepitant Regimen Cycles 2-6 |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 23/152 | 22/150 | 53/170 |
| AnemiaBlood and lymphatic system disorders | 2/152 | 3/150 | 9/170 |
| VomitingGastrointestinal disorders | 2/152 | 3/150 | 8/170 |
| PyrexiaGeneral disorders | 0/152 | 2/150 | 8/170 |
| PancytopeniaBlood and lymphatic system disorders | 3/152 | 6/150 | 4/170 |
| NeutropeniaBlood and lymphatic system disorders | 4/152 | 0/150 | 4/170 |
| Neutrophil count decreasedInvestigations | 1/152 | 2/150 | 4/170 |
| DehydrationMetabolism and nutrition disorders | 0/152 | 1/150 | 4/170 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/152 | 2/150 | 3/170 |
| Mucosal inflammationGeneral disorders | 2/152 | 2/150 | 3/170 |
| Event | Aprepitant Regimen Cycle 1 | Control Regimen Cycle 1 | Aprepitant Regimen Cycles 2-6 |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 24/152 | 35/150 | 62/170 |
| VomiitingGastrointestinal disorders | 21/152 | 20/150 | 59/170 |
| NauseaGastrointestinal disorders | 13/152 | 17/150 | 42/170 |
| NeutropeniaBlood and lymphatic system disorders | 17/152 | 18/150 | 39/170 |
| ThrombocytopeniaBlood and lymphatic system disorders | 15/152 | 14/150 | 38/170 |
| Neutrophil count decreasedInvestigations | 12/152 | 17/150 | 32/170 |
| Plastelet count decreasedInvestigations | 10/152 | 15/150 | 26/170 |
| PyrexiaGeneral disorders | 8/152 | 10/150 | 22/170 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/152 | 5/150 | 18/170 |
| Abdominal painGastrointestinal disorders | 11/152 | 10/150 | 17/170 |
Intent-to-treat (ITT) population: all randomized participants who received study medication.
| Age, Continuous(Months) | Aprepitant Regimen | Control Regimen | Total |
|---|---|---|---|
| Mean | 97.7 ± 63.2 | 99.4 ± 60.9 | 98.5 ± 62.0 |
| Sex: Female, Male(Participants) | Aprepitant Regimen | Control Regimen | Total |
|---|---|---|---|
| Female | 68 | 71 | 139 |
| Male | 84 | 79 | 163 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Sep 2011 to primary completion in Mar 2013, 18 months.
Results were first posted in Apr 2014, 1 year after primary completion.
Of 56 phase 3 interventional studies under Vomiting, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aprepitant